EMA Updates Board On Business Continuity And Coronavirus
Plan Safeguards Core Agency Activities In Light Of Coronavirus Pandemic
The European Medicines Agency’s first management board meeting of 2020 was held virtually and was shortened but covered a number of topics including COVID-19.
You may also be interested in...
The European medicines regulator wants to restrict the number of visitors coming to its offices to reduce the risk of coronavirus infection.
The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. How they perform is critical. Consultant Kate Dion has a raft of helpful tips for companies facing this daunting situation. Neena Brizmohun reports.
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.